Marinus Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 165
- Market Cap
- $80.9M
- Introduction
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded in August 2003 and is headquartered in Radnor, PA.
Immedica Acquires Marinus Pharmaceuticals for $151M, Expanding Rare Disease Portfolio with ZTALMY
Swedish rare disease specialist Immedica Pharma has agreed to acquire Marinus Pharmaceuticals for $151M, strengthening its position in the global rare disease market through a cash tender offer of $0.55 per share.
Marinus Pharmaceuticals Cuts 45% of Workforce After Ganaxolone Trial Failure
Marinus Pharmaceuticals announced a workforce reduction of approximately 45% following disappointing Phase III trial results for oral ganaxolone in tuberous sclerosis complex.
Marinus Pharmaceuticals Focuses on Oral Ganaxolone After Trial Setback
Marinus Pharmaceuticals shifts focus to oral ganaxolone (O-GNX) for tuberous sclerosis complex (TSC) after IV ganaxolone (IV-GNX) fails a Phase 3 trial for refractory status epilepticus (RSE).
Amgen Launches Eylea Biosimilar Pavblu at Discount; GSK Invests $800M in Manufacturing
Amgen has launched Pavblu, its biosimilar to Regeneron's Eylea, at a 10% discount, pricing it at $1,665 per dose, potentially muting its market impact.
Marinus Pharmaceuticals' Ganaxolone Fails Primary Endpoint in Phase III TSC Trial
Marinus Pharmaceuticals' Phase III TrustTSC trial of oral ganaxolone for tuberous sclerosis complex (TSC)-associated seizures did not meet its primary endpoint.
Phase 3 Trial of Oral Ganaxolone Fails to Meet Primary Endpoint in Tuberous Sclerosis Complex
Marinus Pharmaceuticals' Phase 3 TrustTSC trial evaluating oral ganaxolone for tuberous sclerosis complex (TSC)-associated seizures did not meet its primary endpoint.
Marinus Pharmaceuticals' Ganaxolone Fails Phase 3 Trial for Tuberous Sclerosis Complex
Marinus Pharmaceuticals' Phase 3 TrustTSC trial of oral ganaxolone for tuberous sclerosis complex (TSC)-associated seizures did not meet its primary endpoint.
Ganaxolone Shows Promise in Phase III RAISE Trial for Refractory Status Epilepticus
Marinus Pharmaceuticals' RAISE trial evaluated IV ganaxolone for refractory status epilepticus (RSE), meeting one co-primary endpoint.
Marinus Pharmaceuticals Highlights ZTALMY® Progress in Tuberous Sclerosis Complex
Marinus Pharmaceuticals anticipates Phase 3 TrustTSC trial results for ZTALMY® in tuberous sclerosis complex (TSC) in Q4 2024, with NDA filing targeted for April 2025.